0:00
27:40
In this episode, we welcome the lead author of “Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A phase 2, Randomized, Double-Blind, Placebo-Controlled Trial” Dr. Eric Morand of Monash University. The objective of this multicenter clinical trial in lupus (recently published in “Arthritis & Rheumatology”) was to assess the efficacy of deucravacitinib in a phase II trial in adult patients with active lupus. Dr. Morand’s methods, results and ultimate conclusions take center stage of our show today.
Weitere Episoden von „ACR Journals On Air“
Verpasse keine Episode von “ACR Journals On Air” und abonniere ihn in der kostenlosen GetPodcast App.